Subtle Medical has raised $12.2 million in series A funding to pursue geographic expansion of the firm's artificial intelligence (AI) software for medical imaging enhancement.
The funding round was led by 3E Bioventures Capital with participation from Fusion Fund, Data Collective, Delta Capital, Tsingyuan Ventures, and other seed investors. This funding round also included participation by European investors Crista Galli Ventures from the U.K. and Nina Capital from Spain.
Subtle Medical notes its SubtleMR and SubtlePET software are already in use in more than 50 sites around the world.
The new funding will also bolster Subtle's product development, including SubtleGAD, an algorithm for lowering gadolinium dose in contrast-enhanced MRI, the firm said.
![A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/07/2026-07-14-radiology-mammogram-ai-auto-bias.H0bYO8QlWs.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
